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Various tumors metastasize via lymph vessels and
lymph nodes to distant organs. Even though tumors
are hypoxic, the mechanisms of how hypoxia regu-
lates lymphangiogenesis remain poorly character-
ized. Here, we show that hypoxia reduced vascular
endothelial growth factor C (VEGF-C) transcription
and cap-dependent translation via the upregulation
of hypophosphorylated 4E-binding protein 1 (4E-
BP1). However, initiation of VEGF-C translation
was induced by hypoxia through an internal ribo-
some entry site (IRES)-dependent mechanism.
IRES-dependent VEGF-C translation was indepen-
dent of hypoxia-inducible factor 1a (HIF-1a)
signaling. Notably, the VEGF-C IRES activity was
higher in metastasizing tumor cells in lymph nodes
than in primary tumors, most likely because lymph
vessels in these lymph nodes were severely
hypoxic. Overall, this transcription-independent
but translation-dependent upregulation of VEGF-C
in hypoxia stimulates lymphangiogenesis in tumors
and lymph nodes and may contribute to lymphatic
metastasis.
INTRODUCTION
The lymphatic vasculature consists of a network of lymph ves-
sels that drain interstitial fluid from tissues and return it to the
blood. It is also essential for immune surveillance. However,
increased lymphangiogenesis also contributes to tumor metas-
tasis and various inflammatory diseases, while insufficient lymphCvessel growth or dysfunction causes lymphedema (Albrecht and
Christofori, 2011; Alitalo, 2011; Bonnal et al., 2003; Christiansen
and Detmar, 2011; Martinez-Corral and Makinen, 2013). Block-
ing lymphangiogenesis may offer therapeutic benefit to limit
tumor spread.
Hypoxia promotes the growth of blood vessels (angiogen-
esis), but only limited data are available on whether and how
hypoxia regulates lymphangiogenesis. Nevertheless, lymph
vessels are often located in remote areas away from oxygen-
carrying blood vessels and do not contain oxygen-carrying
red blood cells; they are thus exposed to a milieu with very
low oxygen levels (Guzy et al., 2008; Ivanovic, 2009). Some
correlative studies suggest a link among tumor hypoxia, the
hypoxia-inducible transcription factor HIF-1a, and lymphangio-
genesis (Schoppmann et al., 2006; Tao et al., 2006). Another
study reported that HIF-1a promotes lymphatic metastasis
by transcriptional activation of the lymphangiogenic factor
platelet derived growth factor B (Schito et al., 2012). HIF-1a
also stimulates transcription of Prox-1, another lymph-angio-
genic factor (Zhou et al., 2013). However, whether hypoxia
signaling (and in particular HIF-1a) regulates the expression
of vascular endothelial growth factor C (VEGF-C), one of the
key lymphangiogenic factors (Alitalo and Detmar, 2012), re-
mains unknown. Only a single report documented an associa-
tive correlation between HIF-1a and VEGF-C in cancer (Liang
et al., 2008). It is also unknown whether VEGF-C expression
in hypoxic conditions relies on transcriptional or translational
mechanisms.
When cells are exposed to low oxygen levels, they
suppress general protein synthesis in order to save energy
(Kaelin and Ratcliffe, 2008; Majmundar et al., 2010; Maxwell,
2005; Semenza, 2012). Hypoxia inhibits mRNA translation
by affecting the activity of two kinases, mTOR and PERK
(Larsson et al., 2013; Silvera and Schneider, 2009). Inactivationell Reports 6, 155–167, January 16, 2014 ª2014 The Authors 155
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Figure 1. Expression Levels of VEGF-C and
4E-BP1 in Breast Tumor Specimens
(A–F) Immunostaining of VEGF-C in human spec-
imens of healthy breast tissue (A), invasive breast
cancer (B and C), and in healthy (D) and metasta-
sized (E and F) lymph nodes. (C) and (F) show
larger magnification of the framed area of (B) and
(E), respectively.
(G–J) Immunostaining of 4E-BP1 in human healthy
breast epithelium (G), invasive breast cancer (H),
and normal (I) and metastasized (J) lymph nodes.
Scale bar represents 50 mm (A, B, G, and H), 25 mm
(C and F), and 250 mm (D, E, I, and J).of mTOR results in hypophosphorylation of eIF4E-binding
proteins (4E-BP), which promotes the sequestering of
eIF4E, a factor necessary for cap-dependent translation
(Martineau et al., 2013; Richter and Sonenberg, 2005). Hypoxic
activation of PERK is mediated by the unfolded protein
response and inhibits translation by phosphorylating the
translation initiation factor eIF2-a (Koumenis and Wouters,
2006).
Other mRNAs are translated in hypoxic conditions by an
alternative mechanism, mediated by internal ribosome entry
sites (IRESs) located in their 50 UTRs, which allows the ribo-
some to be recruited to a site that is at a considerable distance
from the cap structure, most frequently in the presence of
trans-acting factors (Spriggs et al., 2008; Vagner et al., 2001).
Many cellular mRNAs have now been documented to contain
IRESs. The majority of identified IRESs are found in mRNAs of
proteins that are associated with the control of cell growth
and death, including growth factors, proto-oncogenes and pro-
teins required for apoptosis (Bushell et al., 2004). IRES ele-
ments have also been identified in VEGF-A and fibroblast
growth factor 2 mRNA sequences and are activated by hypoxia
to stimulate angiogenesis (Bornes et al., 2007). However, since
it is unknown if IRES-dependent expression of VEGF-C in hyp-
oxic conditions regulates lymphangiogenesis, we characterized
IRES-dependent induction of VEGF-C in hypoxic tumors and
lymph nodes.156 Cell Reports 6, 155–167, January 16, 2014 ª2014 The AuthorsRESULTS
Coexpression of VEGF-C and 4E-
BP1 in Tumor Cells
We examined by immunohistochemistry
(IHC) the expression levels of VEGF-C in
human healthy breast specimens, tumor
biopsies of invasive ductal carcinomas,
and draining metastatic lymph nodes.
Fifteen tumor biopsy specimens and their
sentinel nodeswere analyzed. Immunore-
active VEGF-C levels were moderate in
healthy tissues but elevated in tumor
samples (Figures 1A–1C). VEGF-C was
undetectable in healthy lymph nodes but
upregulated in metastatic tumor cells in
lymph nodes (Figures 1D–1F).Notably, 4E-BP1, a negative regulator of cap-dependent
mRNA translation, was overexpressed in tumors and metastatic
lymph nodes as compared to healthy epithelium and noninvaded
lymph nodes (Figures 1G–1J). Since overexpression of 4E-
BP1 inhibits cap-dependent translation induced by hypoxia in
tumors (Braunstein et al., 2007), these findings raised the
question whether VEGF-C translation in tumors and metastatic
lymph nodes relied on a cap-independent regulation of VEGF-C
translation.
VEGF-C mRNA Is Reduced while VEGF-C Protein Is
Increased in Tumors
We used three different mouse tumor models known to induce
lymphangiogenesis and to metastasize via lymph vessels:
Capan-1, a xenograft of human pancreatic adenocarcinoma;
4T1, an orthotopic syngeneic mouse model of metastatic breast
cancer; and a syngeneic subcutaneous model of Lewis lung
carcinoma (LLC) (Deer et al., 2010; Garmy-Susini et al., 2010;
Pulaski and Ostrand-Rosenberg, 2001). When studying the
expression of VEGF-C in primary tumor extracts during tumor
progression, we found that VEGF-C mRNA levels were
decreased (Figures 2A–2C), while human VEGF-C protein levels
were increased in the three tumor cell types, as observed by
a human VEGF-C-specific ELISA (Figure 2D) and by immuno-
blotting (Figures 2E and 2F). These data suggested that induc-
tion of VEGF-C expression occurred via a posttranscriptional
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Figure 2. Tumor Lymphangiogenesis Cor-
relates with Posttranscriptional Induction
of VEGF-C In Vivo
(A–C) Quantitative RT-PCR (qRT-PCR) of VEGF-C
mRNA in Capan-1 pancreatic (A), LLC (B), and 4T1
breast (C) tumors shows a decrease of VEGF-C
transcript levels during tumor growth (mean ±
SEM; n = 8–10; *p < 0.001).
(D), ELISA analysis showing increased VEGF-C
protein levels during Capan-1 tumor growth
(mean ± SEM; n = 5, *p < 0.001).
(E and F) Immunoblot of VEGF-C, 4E-BP1, and
eIF2a and phosphorylated eIF2a (p-eIF2a) in
Capan-1 pancreatic, LLC, and 4T1 breast
tumors, showing an increase in VEGF-C protein
levels, associated with increased expression and
dephosphorylation of 4E-BP1 and with increased
phosphorylation of eIF2a when comparing day 14
(Capan-1, 4T1) or day 21 (LLC) with day 7 tumor
protein extracts. Quantification by densitometry is
shown in (F). Relative levels are normalized to
b-tubulin (VEGF-C, hypophosphorylated 4E-BP1)
or to eiF2a (p-eiF2a) (mean ± SEM; n = 8–10; *p <
0.05 **p < 0.01, ***p < 0.001).
(G–L) Immunostaining for LYVE-1 (red) demon-
strating increased lymphangiogenesis during
Capan-1 pancreatic (G andH), 4T1 breast (I and J),
and LLC (K and L) growth. Nuclei are visualized by
DAPI staining (blue).
(M–O) Morphometric quantification of tumor lym-
phatic vessel area (% of tumor area) in Capan-1
(M), 4T1 (N), and LLC (O) tumors (mean ± SEM;
n = 8–10; *p < 0.01).
Scale bar represents 50 mm (G–L). See also
Figure S1.mechanism. Use of murine VEGF-C-specific primers in the
human Capan-1 tumor model revealed that stromal cells did
not compensate for the reduced human VEGF-C mRNA levels
by upregulating murine VEGF-C transcript levels (Figure S1).
Staining for the lymphatic endothelial cell marker LYVE-1 com-
plemented with quantification of lymph vessel area showed
that lymphangiogenesis increased during tumor progression
(Figures 2G–2O), in agreement with the enhanced VEGF-C pro-
tein levels.
We studied the phosphorylation status of 4E-BP1 by immu-
noblotting. 4E-BP1 can be hypophosphorylated (designated
a-form) or hyperphosphorylated (designated b and g forms). In
its hypophosphorylated state, 4E-BP1 inhibits cap-dependent
translation initiation by sequestering eIF-4E (Martineau et al.,
2013; Richter and Sonenberg, 2005). During tumor progression,Cell Reports 6, 155–167total 4E-BP1 protein levels increased and
4E-BP1 became increasingly hypophos-
phorylated, as evidenced by the shift to
a lower molecular weight (Figures 2E
and 2F). We also analyzed eIF2a phos-
phorylation using antibodies recognizing
phosphorylated and total eIF2a, as
eIF2a phosphorylation downregulates
protein synthesis in various stress condi-
tions, including hypoxia (Koumenis andWouters, 2006). Notably, phosphorylated eIF2a (p-eIF2a) levels
increased during tumor progression (Figures 2E and 2F). Thus,
decreased VEGF-CmRNA and increased VEGF-C protein levels,
together with the decrease of global translation initiation in
tumors mediated by 4E-BP and eIF2a, suggested a stress-spe-
cific mechanism of regulation of VEGF-C translation, such as an
IRES-dependent translation process.
Structure Probing of the 50 UTR mRNA of VEGF-C
We therefore explored if VEGF-C might be translated via IRES-
dependent regulation. In order to analyze if the 50 UTRs of the
human and murine VEGF-C contained conserved structural
features, the secondary structures of both RNAs were studied
by using ‘‘selective 20-hydroxyl acylation analyzed by primer
extension’’ (SHAPE) analysis to obtain information on the RNA, January 16, 2014 ª2014 The Authors 157
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Figure 3. VEGF-C mRNA Contains an IRES Element Activated during Tumor Growth
(A) Sequence alignment of the murine and human VEGF-C 50 UTR sequences. A color code is used for each nucleotide: guanine (orange), adenine (green), uridine
(red), and cytosine (blue). Three stretches of nucleotides are highly conserved between the two RNA sequences: motif 1 (light blue), motif 2 (light orange), and
motif 3 (light green).
(B) Quantification of the SHAPE analysis (see the Experimental Procedures) is shown for the conserved nucleotides of motif 3 of the human (orange) and murine
(red) 50 UTRs, showing very similar reactivity patterns.
(C) Putative secondary structure of the murine 50 UTR of VEGF-C mRNA, as predicted on the basis of the ribose reactivities toward SHAPE and the reactivities of
adenines at N1 and cytosines at N3 toward DMS. For each nucleotide, the level of reactivity toward SHAPE is indicated in red, yellow, or black font character for
strong, medium, or weak reactivity, respectively. The cleavage sites induced by ribonucleases V1, T1, or T2 are indicated by arrows. Motifs 2 and 3 are color-
coded as in (A).
(legend continued on next page)
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secondary structure at single nucleotide resolution. SHAPE
takes advantage of the fact that only flexible nucleotides are
reactive toward hydroxyl-selective electrophiles, whereas con-
strained nucleotides are unreactive. We used as chemical prob-
ing reagents benzoyl cyanide in order to provide information on
the flexibility of each ribose (Mortimer and Weeks, 2009) and
dimethyl sulfate (DMS), which methylates single-stranded cyto-
sines at N3 and adenines at N1 (Figure S2A). To footprint and
probe the RNA structure, we also took advantage of the enzy-
matic cleavage by RNase T1 (which cleaves single-stranded
RNA after unpaired guanines residues), RNase T2 (cleaving
single-stranded RNA after unpaired nucleotides with a prefer-
ence for adenines), and RNase V1 (cleaving base-paired nucleo-
tide residues in a non-sequence-specific manner) (Figure S2A).
This analysis revealed that the 50 UTRs were highly structured
because of a high GC content (Figures 3A and 3B; Figures S2A
and S2B). However, the concomitant presence of RNase V1
cleavages and of single-strand specific cuts, together with the
sensitivity to modifications by DMS in the SHAPE analysis, sug-
gested that these RNAs do not fold into a unique fixed structure
but are able to adopt alternative conformations at equilibrium.
Nevertheless, based on the quantification of the DMS and
SHAPE reactivities, the most representative of the putative sec-
ondary structures of the murine 50 UTR is shown in Figure 3C.
Using sequence alignment, we observed three highly conserved
regions between the human and murine 50 UTRs (Figure 3A).
Interestingly, SHAPE analysis revealed that two of these motifs
adopted the same structure, since the reactivity pattern of the
conserved residues was nearly identical (Figure 3B; Figure S2B).
These motifs, located at the same distance from the initiation
codon in human and murine RNAs, might be appropriate for
binding of trans-acting factor(s) necessary to activate IRES-
dependent translation.
The 50 UTR of VEGF-C Exhibits IRES Activity
We then explored if the putative IRES sequences in the human
and murine 50 UTR of the VEGF-C mRNAs were translationally
active and cloned these sequences in a double luciferase bicis-
tronic vector (Figure 3D) (Cre´ancier et al., 2000). In this vector,
the first Renilla luciferase (LucR) cistron is translated by a cap-
dependent mechanism, while the second firefly luciferase
(LucF) cistron can be translated only if an IRES is present
between the two cistrons. We used bicistronic vectors contain-
ing the encephalomyocarditis virus (EMCV) IRES sequence since
it is not or only minimally regulated in mammalian cells, and we
also used the VEGF-A IRES since it is activated by hypoxia
(Bornes et al., 2007) (the VEGF-A data are discussed below).
An empty control bicistronic vector, containing a sequence
without IRES activity between the two cistrons, was inactive (Fig-(D) Schematic representation of the bicistronic expression cassettes subcloned
dependent translation (Renilla luciferase) or by IRES-dependent translation (firefly
VEGF-A IRES, as well as the viral EMCV IRES (EMCV) and a short sequence dev
(E and F) mRNA expression analysis of firefly luciferase (LucF) and Renilla lucife
containing human (E) or murine (F) VEGF-C 50 UTR, revealing comparable expr
(mean ± SEM; n = 6; p = NS).
(G and H) In vivo VEGF-C (G) and EMCV (H) IRES activity in Capan-1, 4T1, and L
See also Figure S2.
Cure 3D; Figure S2C). Control RT-PCR analysis showed that both
proteins were translated from a single mRNA transcript, since
comparable amounts of LucR and LucF mRNA were measured
(Figures 3E and 3F), indicating that a cryptic promoter or splicing
event did not influence the results (Martineau et al., 2004).
To quantify the IRES activity in human and murine VEGF-C
50 UTR sequences in vivo, Capan-1, 4T1, and LLC tumor cells
were transduced with the bicistronic lentiviral vectors and in-
jected subcutaneously (Capan-1, LLC) or orthotopically in the
mammary fat pad (4T1). We used the human VEGF-C 50 UTR
for the human cell line (Capan-1) and the murine VEGF-C
50 UTR for the murine cell lines (4T1, LLC). Transduction of the
bicistronic vector did not affect tumor growth (Figures S2D and
S2E). The VEGF-C IRES activity was quantified by measuring
the LucF/LucR ratio as a parameter of the relative contribution
of IRES-dependent versus cap-dependent translation after 7,
14, and 21 days. The IRES activity levels at day 14 and 21
were expressed relative to the IRES activity at day 7. These ex-
periments revealed an IRES activity for both human and murine
VEGF-C 50 UTRs (Figures 3G and 3H). Furthermore, this IRES
activity increased during tumor progression, especially in breast
and lung tumors, while the EMCV IRES activity changed only
minimally in 4T1 tumors (1.68-fold), e.g., less than the VEGF-C
IRES activity in these tumors (3.75-fold).
The VEGF-C IRES Activity Is Higher in Metastatic Lymph
Nodes
Analysis of the LYVE-1-positive lymphatic area in Capan-1, 4T1,
and LLC tumors showed that lymphangiogenesis in lymph nodes
was minimal at 3 days after inoculation but progressively
increased from 7 days onward (Figures 4A–4J). This raised the
question whether VEGF-C protein synthesis was increased in
metastatic lymph nodes. However, substantial numbers of met-
astatic cytokeratin-positive tumor cells were detected in draining
lymph nodes of Capan-1 and 4T1 tumors only from 14 days
onward and of LLC tumors only from 21 days onward, i.e., later
than the first signs of increased lymphangiogenesis in metastatic
lymph nodes (Figures 4K–4N). Previous reports already docu-
mented that lymph node lymphangiogenesis precedes lymph
node metastasis, presumably because primary tumors release
VEGF-C in the lymph fluid of efferent lymphatics (Hirakawa,
2009).
We also explored whether tumor cells might upregulate
VEGF-C production to higher levels, once they had intravasated
and traveled through lymph vessels to the lymph node, and
therefore analyzed the VEGF-C IRES activity in draining lymph
nodes to which tumor cells metastasized. In order to compare
the IRES activity in tumors and metastatic lymph nodes, the
firefly/Renilla luciferase ratio in each tumor type was normalizedin lentivectors, encoding two luciferase reporters that are translated by cap-
luciferase). IRESs used are the murine and human VEGF-C 50 UTR, the human
oid of IRES as positive and negative controls, respectively.
rase (LucR) by qRT-PCR on cells transduced with the bicistronic lentivector
ession of LucR and LucF mRNA, suggesting transcription of a single mRNA
LC tumors (values are relative to day 7; mean ± SEM; n = 8–10; *p < 0.01).
ell Reports 6, 155–167, January 16, 2014 ª2014 The Authors 159
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Figure 4. VEGF-C IRES Activity Is Higher in Metastatic Tumor Cells in the Lymph Node
(A–I) Staining for LYVE-1 (red) and nuclei (DAPI, blue) at day 3 (A–C), 7 (D–F) and 14 (G and H) or 21 (I) revealed that lymphangiogenesis progressively increased in
tumor-draining lymph nodes in Capan-1, 4T1, and LLC tumors. Dashed lines denote the border of the tissue.
(J) Quantification of lymphatic vessel area in lymph node (mean ± SEM; n = 8–10; *p < 0.05, ***p < 0.001).
(K–M) Staining for cytokeratin (green, see arrowheads) and nuclei (DAPI, blue) revealedmetastatic dissemination to lymph node of Capan-1, 4T1 and LLC tumors.
Dashed lines denote the border of the tissue.
(N) Quantification of metastasis positive lymph nodes (mean ± SEM; n = 8–10; ***p < 0.001).
(O) In vivo VEGF-C- and EMCV-IRES activity in metastatic lymph nodes of Capan-1, 4T1, and LLC tumors at 14, 14, and 21 days, respectively (values are
expressed relative to the respective value in the tumor; mean ± SEM; n = 8–10; *p < 0.01).
Scale bar represents 50 mm (all).to the value of 1, both for the EMCV and VEGF-C IRES, and the
IRES activities in the lymph nodes were expressed as a fold
induction over the IRES activity in the tumor. This analysis re-
vealed that compared to primary tumors, the VEGF-C IRES
activity in metastatic lymph nodes was 5-, 7-, and 18-fold higher
in the Capan-1, 4T1, and LLC tumor models at 14, 14, and
21 days after tumor inoculation, respectively, while the EMCV
IRES activity was not affected (Figure 4O). These findings sug-
gested that the lymphatic milieu influenced VEGF-C translation
in tumor cells.
LymphVessels AreHypoxic andDevelopNearbyHypoxic
Tumor Cells
We then sought to determine why the lymphatic milieu enhanced
the VEGF-C IRES activity in metastatic tumor cells. Since lym-
phatics are known to be hypoxic (Guzy et al., 2008; Ivanovic,160 Cell Reports 6, 155–167, January 16, 2014 ª2014 The Authors2009) and IRES elements are activated in cellular stress condi-
tions such as hypoxia (Braunstein et al., 2007; Komar and Hatzo-
glou, 2011; Pestova et al., 2001; Sachs, 2000; Silvera and
Schneider, 2009; Spriggs et al., 2010; Vagner et al., 2001), we
explored whether hypoxia affected IRES-dependent initiation
of translation of VEGF-C. We first explored a possible link
between hypoxia and lymphatic development and therefore
double stained tumors for the hypoxyprobe pimonidazole and
the lymphatic markers LYVE-1 or podoplanin. Already at an early
stage of tumor development (in <5 mm3 tumors), the pancreas,
breast, and lung cancer models contained hypoxic regions,
which becamemore widespread and stained more strongly after
2 weeks (Figures 5A–5C). Immunoblotting for HIF-1a confirmed
activation of this hypoxia-inducible transcription factor (Fig-
ure 5D). In all cancer models, lymph vessels developed in prox-
imity of hypoxic tumor cell clusters (Figures 5E–5G). Unlike blood
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Figure 5. Tumor VEGF-C Levels Are
Increased in Hypoxic Zones
(A–C) Immunodetection of hypoxic areas (hypo-
xyprobe, brown) in Capan-1 tumors revealed few
small hypoxic areas at early time points (A, day 7),
which became more abundant by 14 days after
injection (B). Arrowheads indicate pimonidazole
adduct (PIMO)-positive hypoxic areas. Quantifi-
cation of PIMO+ area is shown in (C) (mean ± SEM;
n = 10; *p < 0.001).
(D) Immunoblot for HIF-1a in Capan-1 tumors
showing stabilization of the protein in vivo. Normal
healthy skin was used as control. Densitometric
quantification is shown (mean ± SEM; n = 6; ***p <
0.001). ctrl, control.
(E–G) Staining for LYVE-1 (green, see arrowheads)
revealing the presence of lymphatic vessels close
to hypoxic areas (hypoxyprobe [PIMO], brown) in
Capan-1 (E), 4T1 (F), and LLC (G) tumors.
(H–J) Staining of Capan-1 tumor for LYVE-1
(green, arrowhead) and hypoxyprobe (PIMO,
brown) revealed hypoxic lymph vessels. Merged
image is shown in (J).
Scale bar represents 50 mm (A andB), 50 mm (E–G),
25 mm H–J). See also Figure S3.endothelial cells, lymphatic endothelial cells also stained posi-
tively for pimonidazole, indicating that lymph vessels are hypoxic
(Figures 5H–5J; Figures S3A–S3F).
Hypoxia Induces VEGF-C Expression by a
Nontranscriptional Mechanism
We then studied the regulation of IRES-dependent VEGF-C
translation by hypoxia. Immunostaining revealed that VEGF-C
and LucF were expressed predominantly in pimonidazole-posi-
tive hypoxic tumor areas in vivo (Figures 6A–6F). To study the
effect of hypoxia on VEGF-C expression in vitro, we exposed
LLC, Capan-1, or 4T1 tumor cells to 1%oxygen or to cobalt chlo-
ride (CoCl2), known to activate hypoxia signaling. Hypoxia
reduced VEGF-C mRNA levels in LLC and 4T1 cells while not
affecting its levels in Capan-1 cells (Figures 6G–6I). In LLC and
4T1 cells, hypoxia increased the protein levels of VEGF-C and
of hypophosphorylated 4E-BP1, suggesting increased VEGF-C
production despite a decrease in cap-dependent initiation ofCell Reports 6, 155–167translation (Figures 6J and 6K). In
Capan-1 cells, VEGF-C protein levels
were comparable in hypoxic conditions,
though 4E-BP1 dephosphorylation was
increased, suggesting that the reduced
cap-dependent initiation of VEGF-C
translation was balanced off by an in-
crease in IRES-dependent initiation of
VEGF-C translation (Figures 6J and 6K).
In each cell line, eIF2a phosphorylation
was increased by hypoxia, suggesting
that hypoxia downregulated global
mRNA translation (Figures 6J and 6K).
Since hypoxia increased the VEGF-C
IRES activity in all human and murinetumor lines (also in the Capan-1 cells, in which VEGF-C levels
did not increase) (Figures 6L–6N), hypoxia thus induced a switch
from cap-dependent to IRES-dependent initiation of VEGF-C
translation. Similar results were obtained when we used CoCl2
(Figure 6O). Phosphorylation of eIF2a inhibits the EMCV IRES
activity (Sanz et al., 2013) and the increased eIF2a phosphoryla-
tion levels might thus be responsible for the inhibition of the
EMCV IRES activity in hypoxia, while the variable EMCV IRES
activity in hypoxia in distinct tumor cell lines likely reflects cell-
type-dependent regulation of this IRES activity, which has
been recognized previously (Pilipenko et al., 2000).
The VEGF-C IRES Activity Is Reduced in More
Oxygenated Tumors
We then explored whether tumor oxygen levels in vivo influ-
enced the switch between cap-dependent VEGF-C translation
(in oxygenated conditions) versus IRES-dependent VEGF-C
translation (in hypoxic conditions). We therefore used prolyl, January 16, 2014 ª2014 The Authors 161
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Figure 6. Hypoxia Induces VEGF-C-IRES Activity In Vitro
(A–C) Staining for VEGF-C (red) and hypoxyprobe (PIMO, brown) revealed VEGF-C colocalization (arrows) in hypoxic areas in Capan-1 (A), 4T1 (B), and LLC (C)
tumors. Dashed lines denote more hypoxic from more normoxic zones.
(D–F) Staining for firefly luciferase (LucF, red) and hypoxyprobe (PIMO, brown) revealed IRES-dependent luciferase translation (arrows) primarily in hypoxic areas
in Capan-1 (D), 4T1 (E), and LLC (F) tumors. Dashed lines denote more hypoxic from more normoxic zones.
(G–I) qRT-PCR for VEGF-C showing reduced mRNA levels in hypoxic conditions in LLC (G) and 4T1 (I) tumor cells, but not in Capan-1 tumor cells (H) (mean ±
SEM; n = 9, *p < 0.001 in I; #p = 0.059 in G; p = NS in H).
(J and K) Immunoblot of VEGF-C, 4E-BP1, eIF2a, and phosphorylated eIF2a (p-eIF2a) in Capan-1, LLC, or 4T1 tumor cells, cultured in normoxia or hypoxia
(1% O2). Quantification by densitometry is shown in (K). Relative levels are normalized to b-tubulin (VEGF-C, hypophosphorylated 4E-BP1) or to eiF2a (p-eiF2a)
(mean ± SEM; n = 3–6; *p < 0.05, **p < 0.01).
(L–N) VEGF-C- and EMCV IRES activity under normoxic and hypoxic conditions (1% O2) in Capan-1 (L), 4T1 (M), and LLC (N) tumor cells in vitro (values are
expressed relative to the respective normoxia condition; mean ± SEM; n = 6; *p < 0.01 versus normoxia).
(O) VEGF-C- and EMCV IRES activity in control and CoCl2 conditions in Capan-1 and LLC cells in vitro (values are expressed relative to the respective controls;
mean ± SEM; n = 5; *p < 0.01).
Scale bar represents 50 mm (A–F). ctrl, control.hydroxylase domain protein-2 (PHD2)+/ mice, in which tumor
hypoxia is reduced because of normalization of tumor blood
vessels and improved tumor vessel perfusion (Mazzone et al.,
2009), hypothesizing that the VEGF-C IRES activity would be
reduced in these mice. We thus implanted bicistronic luciferase
vector-transduced LCC tumor cells in wild-type (WT) and
PHD2+/ mice. Tumor growth of cancer cells, transduced
with VEGF-C- or EMCV-IRES vectors, was comparable in WT
and PHD2+/ mice (Figure S4A), consistent with reports that
PHD2 haplodeficiency did not affect tumor growth (Mazzone162 Cell Reports 6, 155–167, January 16, 2014 ª2014 The Authorset al., 2009). Also, staining for the hypoxia marker pimonidazole
demonstrated that hypoxia levels were lower in EMCV IRES-
and VEGF-C IRES-expressing tumors in PHD2+/ mice than
in WT mice (Figures 7A, 7D, and 7G).
Compared to tumors in WTmice, tumors in PHD2+/mice had
similar VEGF-C immunoreactive protein levels,which colocalized
in part with the pimonidazole-positive hypoxic regions, showing
that both normoxic and hypoxic tumor cells produced VEGF-C
(Figures 7B, 7C, 7E, 7F, and 7H). Immunoblotting confirmed
these findings (Figure S4B). However, a reduced fraction of
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Figure 7. VEGF-C Induction by Hypoxia Is
Translationally Regulated but HIF-1a Inde-
pendent
(A–F) Immunostaining for hypoxyprobe (pimonida-
zole, green) and VEGF-C (red) in LLC tumors in wild-
type (WT) (A–C) and PHD2+/ mice (D–F).
(G) Quantification of pimonidazole-positive pixel
density in tumors transduced with EMCV- or
VEGF-C IRES luciferase constructs showed a
decrease in hypoxia in PHD2+/ mice (mean ± SEM;
n = 6; *p < 0.05).
(H) Quantification of VEGF-C-positive pixel density
in tumors transduced with EMCV- or VEGF-C IRES
luciferase lentivector constructs revealing no differ-
ences (mean ± SEM; n = 8–10; p = NS).
(I–O) Staining for firefly luciferase (LucF, red)
and hypoxyprobe (pimonidazole, green) revealed
reduced VEGF-C IRES-dependent translation in
LLC-bearing PHD2+/ mice (L–N) as compared to
WT mice (I–K). Quantification of LucF-positive pixel
density is shown in (O) confirming the decrease in
luciferase signal for VEGF-C-IRES, which was not
seen with the EMCV control IRES (mean ± SEM;
n = 8–10; *p < 0.01).
(P–R) Micrographs of LLC tumor sections in
PHD2+/ mice, stained for LYVE-1 (green) and hy-
poxyprobe (PIMO, brown), revealing that lymph
vessels were hypoxic in this model.
(S) Immunoblot of VEGF-C or HIF-1a in lysates of
Capan-1 cells incubated in normoxia or hypoxia and
treated with or without siRNA against HIF-1a (siHIF)
or a scrambled siRNA control (siScramble). Densi-
tometric quantification is shown in the graph (right)
(mean ± SEM; n = 4; *p < 0.01).
(T) VEGF-C IRES activity in Capan-1 cell lines in vitro
incubated under normoxia or hypoxia and treated
with or without siRNA against HIF-1a or a scrambled
siRNA control (mean ± SEM; n = 5; ***p < 0.001).
(U) VEGF-A IRES activity in Capan-1 tumors in vivo
revealing increased IRES activity with tumor pro-
gression (mean ± SEM; n = 8–10; *p < 0.005).
(V) Quantification of staining for firefly luciferase
(LucF) revealed that VEGF-A IRES activity was lower
in LLC tumors in PHD2+/mice than inWTmice. The
activity of EMCV IRES was not affected (mean ±
SEM; n = 6; *p < 0.01). Note: since the data shown in
Figure 7V and Figure 7Owere generated in the same
experiments, the EMCV control data are the same.
(W and X) qRT-PCR for VEGF-A showing increased
mRNA levels in hypoxic conditions in Capan-1 (C)
and LLC (D) tumor cells in vitro (mean ± SEM; n = 6;
*p < 0.05).
Scale bar represents 50 mm (all). See also Figure S4.VEGF-C was translated via IRES-dependent mechanisms in the
more oxygenated tumors of PHD2+/mice. Indeed, when double
staining for pimonidazole and firefly luciferase (LucF), VEGF-C
IRES-expressing tumors in PHD2+/ mice had reduced LucF
but increased LucR levels (Figures 7I–7O; Figures S4C and
S4D), indicating that the VEGF-C IRESactivity was reducedwhile
cap-dependent translation initiation was increased. VEGF-C
IRES-dependent translation of LucF was only detected in the
residual hypoxic tumor zones in PHD2+/ mice (Figures 7L–
7N). Interestingly, even though overall tumor oxygenation in
PHD2+/micewas improved because of blood vessel normaliza-Ction, lymph vessels remained immunoreactive for the hypoxyp-
robe pimonidazole in tumors of PHD2+/ mice (Figures 7P–7R).
Thus, IRES-dependent VEGF-C translation was reduced in
more oxygenated tumors of PHD2+/mice, confirming the regu-
lation of the translational switch (cap versus IRES dependence)
by oxygen levels in vivo. That VEGF-C protein levels were not
lower in tumors of PHD2+/mice than inWTmice, despite overall
improved oxygenation, may be due to the fact that the oxygena-
tion conditions in tumors of PHD2+/ mice were still not
sufficiently improved to completely abrogate IRES-dependent
VEGF-C translation. In addition, even though HIF-1a levels areell Reports 6, 155–167, January 16, 2014 ª2014 The Authors 163
reduced in more oxygenated tumors of PHD2+/ mice (Mazzone
et al., 2009), the residual HIF-1a levels may still promote cap-
dependent translation, since HIF-1a induces the transcription
of the cap-binding factor eIF-4E (Yi et al., 2013).
HIF-1a-Independent Hypoxic Induction of VEGF-C
Synthesis
To explore if VEGF-C protein production in hypoxic conditions
was HIF dependent, we used a small interfering RNA (siRNA)
against humanHIF-1a (siHIF) to silenceHIF-1a expression,which
reduced HIF-1a protein levels to nearly undetectable levels in
hypoxic Capan-1 tumor cells (Figure 7S). Silencing of HIF-1a
also reduced the expression levels of VEGF-A, phosphoglycerate
kinase (PGK), hexokinase-2, and the glucose transporter
GLUT-1, all known HIF-1a target genes (Figure S4E). Despite
the strong decrease of the HIF-1a levels in hypoxic Capan-1
tumor cells transfected with siHIF (Figure 7S), VEGF-C protein
levelsweremaintained inhypoxic conditions (Figure7S),whereas
the VEGF-C IRES activity was not affected by HIF-1a silencing
(Figure 7T). Thus, these data suggest that the posttranscriptional
induction of VEGF-C via IRES was independent of HIF-1a.
Regulation of VEGF-A Expression by Hypoxia
For reasons of comparison, we also studied the relative impor-
tance of the cap-dependent versus IRES-dependent translation
of VEGF-A in hypoxia. Previous in vitro studies documented that
VEGF-A translation relies on cap-dependent mechanisms in nor-
moxia and on IRES-dependent mechanisms in hypoxia (Bornes
et al., 2004). Transgenic mouse lines, expressing reporter genes
under the control of IRESs, also revealed that VEGF-A translation
in ischemic muscle partly depends on the IRES activity (Bornes
et al., 2007). However, it is unknown whether IRES-dependent
translation of VEGF-A can also occur in tumors or metastatic
lymph nodes. When tumor cells, stably transduced with a bicis-
tronic lentiviral vector containing the VEGF-A IRES sequence,
were injected in vivo, theVEGF-A IRESactivity levelsweredetect-
able and increased during tumor progression (Figure 7U). The
VEGF-A IRES activity was sensitive to oxygen levels in tumors
in vivo, since tumors (transducedwith lentiviral bicistronic vectors
containingVEGF-A IRES) had lowerVEGF-A IRESactivity levels in
PHD2+/ mice, as revealed by staining for firefly luciferase (Fig-
ure 7V). This was not influenced by the tumor size, since tumor
growth was not affected by the PHD2 genotype or type of bicis-
tronic vector (VEGF-A- or EMCV-IRES) (Figure S4F).
However, different from VEGF-C, regulation of VEGF-A
expression also relied on transcriptional upregulation in hypoxic
conditions. Indeed, VEGF-A mRNA levels were increased in
tumor cells in hypoxia (Figures 7W and 7X) and also increased
during tumor progression in vivo, both at the protein and mRNA
levels (Figures S4G–S4J). Thus, unlike VEGF-A, the expression
of which is upregulated in hypoxia at the transcriptional and
translational level, the expression of VEGF-C in hypoxia is regu-
lated by translational, but not by transcriptional, mechanisms.
DISCUSSION
We identified a translational regulation of VEGF-C production in
hypoxic conditions, both in primary tumors and in (pre)-metasta-164 Cell Reports 6, 155–167, January 16, 2014 ª2014 The Authorstic lymph nodes, that is distinct from previously identified mech-
anisms of how hypoxia stimulates lymphangiogenesis.
Tumor Cells Metastasizing via Hypoxic Lymphatics
Induce VEGF-C
For tumor cells to spread to distant organs via lymphatics, they
induce lymphangiogenesis. However, since tumors are often
deprived of oxygen and lymphatics are extremely hypoxic
(Guzy et al., 2008; Ivanovic, 2009), tumor cells must have mech-
anisms to stimulate lymph vessel growth in hypoxic conditions.
Our findings demonstrate that tumor cells can upregulate
VEGF-C protein levels in hypoxic conditions in vitro and in vivo
and that lymph vessels grew in and around hypoxic tumor areas,
where VEGF-C was produced. While hypoxia often upregulates
protein levels via HIF-1a-dependent gene transcription, this
study shows that hypoxia augments VEGF-C protein levels via
a HIF-1a-independent effect on VEGF-C IRES-dependent initia-
tion of translation.
Hypoxia Regulates VEGF-C Protein Levels via an
IRES-Dependent Activity
We demonstrate that murine and human VEGF-C mRNAs are
translated by IRES-dependent initiation of translation in hypoxic
tumor areas during tumor development in vivo. Sequence align-
ment revealed that murine and human VEGF-C 50 UTRs share
three highly conserved motifs. Interestingly, probing the RNA
secondary structures by SHAPE analysis showed that two of
these motifs adopt the same two-dimensional structure, since
the reactivity pattern of the conserved residues was nearly
identical. These motifs, located at the same distance from the
initiation codon, might be appropriate for binding of specific
trans-acting factor(s), necessary to activate IRES-dependent
translation. Use of a bicistronic vector provided functional evi-
dence that the 50 UTR of murine and human VEGF-C mRNA
indeed functioned as IRES sequences to initiate cap-indepen-
dent translation of the VEGF-C mRNA. Thus, translation of the
VEGF-CmRNA in normoxia occurs via cap- and/or IRES-depen-
dent mechanisms. In hypoxia, when global translation is sup-
pressed through dephosphorylation of 4E-BP1 and increased
phosphorylation of eIF2a, IRES-mediated mRNA translation is
activated, leading to an overall increase in VEGF-C protein
levels.
VEGF-C IRES Activity Is Higher in Lymph Nodes
Previous studies reported that expression of VEGF-C by cancer
cells promotes tumor and lymph node lymphangiogenesis as
well as metastasis (Hirakawa et al., 2005, 2007). Even before
metastatic tumor cells reach the sentinel lymph nodes, VEGF-C,
released by malignant cells of the primary tumor into the
lymphatic circulation, stimulates lymphangiogenesis in lymph
nodes at a distance (Hirakawa et al., 2005, 2007). Using lucif-
erase reporters of posttranscriptional VEGF-C regulation, we
observed that the VEGF-C IRES firefly luciferase activity was
increased in lymph nodes at the time when they were colonized
by metastatic tumor cells. Notably, however, the induction of
the VEGF-C IRES activity was higher in tumor cells that had
metastasized to the lymph nodes than in tumor cells that were
present in the primary tumors. Lymphangiogenesis was also
more extensive in metastatic lymph nodes than in primary
tumors. These data indicate that the lymph node milieu stimu-
lates VEGF-C expression. Since lymphatics are highly hypoxic,
the hypoxic milieu seems to be of key importance to activate
IRES-dependent VEGF-C translation.
HIF-1a-Independent Regulation of VEGF-C Translation
in Hypoxia
Hypoxia signaling is well known to stimulate angiogenesis, in
part by promoting HIF-1a dependent transcription of VEGF-A
as well as by stimulating IRES-dependent VEGF-A translation
(Bornes et al., 2007; Huez et al., 2001). In contrast, VEGF-C tran-
script levels were reduced, yet VEGF-C protein levels were
increased, in hypoxia by switching from cap-dependent to
IRES-dependent VEGF-C translation. Notably, this regulation
seemed to be independent of HIF-1a, since near-complete
silencing of HIF-1a to levels sufficient to lower HIF-1a target
gene transcription did not abrogate the hypoxia-induced post-
transcriptional IRES-activated translation of VEGF-C mRNA
and production of VEGF-C protein. Different molecular mecha-
nisms thus evolved to ensure production of VEGF-A and
VEGF-C, two closely related and homologous members of the
VEGF family.
Hypoxic Lymph Vessels Ensure Lymphangiogenesis in
Cancer
Our findings may also be relevant to understand how tumor
cells have developed mechanisms to ensure spreading via
lymphatics in oxygen-deprived conditions. Lymph vessels are
severely hypoxic, not only because they lack oxygen-carrying
red blood cells, but also because they reside in very hypoxic
regions in tissues and tumors (Guzy et al., 2008; Ivanovic,
2009). Such a hypoxic milieu suppresses cap-dependent
mRNA translation of VEGF-C in tumor cells, traveling inside
lymphatics to the lymph nodes. However, by switching to
IRES-dependent initiation of translation of VEGF-C, tumor
cells can upregulate the production of this key lymphangio-
genic factor in hypoxia and thereby ensure increased growth
of lymph vessels via which they metastasize. Hence, tumor
cells have adopted mechanisms to stimulate lymphangiogene-
sis when metastasizing through hypoxic lymph vessels and
lymph nodes.
EXPERIMENTAL PROCEDURES
All human tissue was used under approval from the Human Subjects Institu-
tional Review Board of the University of Toulouse III. More detailed procedures
are described in Supplemental Experimental Procedures.
Tissue Specimens
In total, 15 primary human breast cancer specimens and their associated
lymph nodes were collected from pretreatment surgical resections (Rangueil
Hospital, Toulouse, France). Sample collection was approved by the INSERM
Institutional Review Board (DC-2008-463) and Research State Department
(Ministe`re de la Recherche, ARS, CPP2, authorization AC-2008-820).
Cell Culture
Cell culture of Capan-1 pancreatic carcinoma cells, 4T1 breast carcinoma,
and LLC cells under normoxia or hypoxia (1% O2 or 300 mM CoCl2) was as
described in the Supplemental Experimental Procedures.CTumor Studies and Immunohistochemical Phenotyping
Animal experiments were conducted in accordance with recommendations of
the European Convention for the Protection of Vertebrate Animals used for
experimentation and according to the INSERM IACUC (France) and the KU
Leuven (Belgium) guidelines for laboratory animal husbandry. All animal
experiments were approved by the local branch Inserm Rangueil-Purpan of
the Midi-Pyre´ne´es ethics committee, France (protocol 091037615), or by the
Institutional Animal Care and Research Advisory Committee of the KU Leuven,
Leuven, Belgium (protocol P166/2011). The LLC syngenic tumor model in
C57Bl6 mice, Capan-1 xenograft model in NMRI nude mice, syngenic ortho-
topic 4T1 breast carcinoma model in Balb/c mice, and the collection and
immunohistological analysis of tumor and lymph nodes was performed as
detailed in the Supplemental Experimental Procedures.
RNA and Protein Analysis
SHAPE Analysis
In-vitro-transcribed RNA was prepared and subjected to SHAPE analysis as
previously described (Helfer et al., 2013) (Mortimer and Weeks, 2009) and
further detailed in the Supplemental Experimental Procedures.
RNA Analysis
Expression of human andmurine VEGF-C, VEGF-A, hexokinase II, Glut1, PGK,
LucR, and LucF was by SYBR green quantitative RT-PCR (Table S1) as
described in the Supplemental Experimental Procedures.
Protein Analysis
VEGF-C protein levels in Capan-1 tumor extracts were measured by ELISA
(R&D Systems).
Lentivector Construction and Luciferase Reporter Gene Assay
Cloning of the cDNAs coding human and murine VEGF-C 50 UTR, VEGF-A
50 UTR, and EMCV 50 UTR into the bicistronic lentivectors expressing Renilla
luciferase under the cytomegalovirus promoter and firefly luciferase under
the control of the respective 50 UTR IRES, and cell transduction was as
described in the Supplemental Experimental Procedures. In vitro or ex vivo
luciferase assays on cell or tissue lysates were performed using the Dual-
Luciferase Assay System kit (Promega).
siRNA and Cell Transfection
siRNA-mediated silencing of humanHIF1awas done using a pool of siRNAs as
listed in the Supplemental Experimental Procedures. Transfection of Capan-1
cells and verification of silencing by immunoblotting was as described in the
Supplemental Experimental Procedures.
Statistical Analysis
All statistical analyses were performed with a two-tailed Student’s t test or
one-way ANOVA. All experiments were performed three times, with one
exception, where the incidence of metastasis is reported as the average ±
SEM of three separate animal experiments. All other data presented are of
one representative experiment.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2013.12.011.
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